The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)
Abstract
In tyrosinaemia type I (McKusick 276700), fatal liver disease results either because of liver failure during infancy or early childhood or because of development of hepatocellular carcinoma during childhood or adolescence. This is caused by toxic metabolites which accumulate because of deficiency of fumarylacetoacetase, the last enzyme in the tyrosine catabolic pathway. NTBC is a potent inhibitor of 4‐hydroxyphenylpyruvate dioxygenase and has been shown to efficiently prevent tyrosine degradation, and production of succinylacetone, in patients with tyrosinaemia. Since the first trial of NTBC treatment for tyrosinaemia type I in 1991, over 220 patients have been treated by the drug using a protocol which includes regular follow‐up with reports of clinical and laboratory investigations to the study centre in Gothenburg, where additional analysis of critical variables is done on regularly collected samples. The course of the disease in patients with acute tyrosinaemia has changed dramatically. Only 10% of the patients have not clinically responded to NTBC treatment. In half of these patients, successful liver transplantation has been performed which has further reduced the mortality rate during infancy to 5%. The international NTBC study has now been going for 5 years and data have emerged that indicate a decreased risk for early development of hepatocellular carcinoma in patients who started treatment at an early age. There are now 101 patients aged 2–8 years who have started NTBC treatment before 2 years of age, and no cancer has developed after 2 years of age among these patients. However, there is no safe age with respect to occurrence of liver cancer, which has been recognized at diagnosis at 1 year of age in one patient and after a few months of treatment in an infant who was given NTBC at 5 months of age.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Eye complications do not appear to be common [16,39] but periodic eye examination with a slit lamp may be indicated (for example annually).”
From Recommendations for the management of tyrosinaemia type 1 (2013) · cites this paper as [16]
In the citing paper
“As the plasma concentrations in individuals are variable [16], if rapid assay of plasma nitisinone level is available it may be useful in detecting problems.”
From Recommendations for the management of tyrosinaemia type 1 (2013) · cites this paper as [16]
In the citing paper
“On the standard dose of 1 mg/kg/d, the plasma concentrations in individuals that suppress SA are variable [16,20].”
From Recommendations for the management of tyrosinaemia type 1 (2013) · cites this paper as [16]
In the citing paper
“The risk of long term complications is also reduced [16].”
From Recommendations for the management of tyrosinaemia type 1 (2013) · cites this paper as [16]
Citations
Cites
Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
LINDSTEDT, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)92685-9 · Cited by 631
Self-citationOn the enzymic defects in hereditary tyrosinemia.
Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447
Self-citationGrompe, M., Lindstedt, S., Al-Dhalimy, M., Kennaway, N. G., Papaconstantinou, J., Torres-Ramos, C. A., Ou, C.-N., & Finegold, M. (1995) · Nature Genetics · doi:10.1038/ng0895-453 · Cited by 312
Self-citationThe occurrence of hepatoma in the chronic form of hereditary tyrosinemia
Weinberg, A. G., Mize, C. E., & Worthen, H. G. (1976) · The Journal of Pediatrics · doi:10.1016/s0022-3476(76)80259-4 · Cited by 283
Neurologic Crises in Hereditary Tyrosinemia
Mitchell, G. A., Larochelle, J., Lambert, M. A., Michaud, J., Grenier, A., de Baulny, H. O., Gauthier, M., Lacroix, J., Vanasse, M., Larbrisseau, A., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220704 · Cited by 230
Van Spronsen, F. J., Thomasse, Y., Smit, P. G. A., Leonard, J. V., Clayton, P. T., Fidler, V., Berger, R., & Heymans, H. S. A. (1994) · Hepatology · doi:10.1002/hep.1840200513 · Cited by 193
Self-induced correction of the genetic defect in tyrosinemia type I.
Kvittingen, E. A., Rootwelt, H., Berger, R., & Brandtzaeg, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117509 · Cited by 168
Ellis, M. K., Whitfield, A. C., Gowans, L. A., Auton, T. R., Provan, W. M., Lock, E. A., & Smith, L. L. (1995) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1995.1121 · Cited by 114
Lock, E. A., Ellis, M. K., Gaskin, P., Robinson, M., Auton, T. R., Provan, W. M., Smith, L. L., Prisbylla, M. P., Mutter, L. C., & Lee, D. L. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005458703363 · Cited by 109
Hereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect
Kvittingen, E. A., Rootwelt, H., Brandtzaeg, P., Bergan, A., & Berger, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116393 · Cited by 102 · cited 2×
“In older patients, the low production may in part be due to self-induced correction of the fumarylacetoacetase defect (Kvittingen et al 1993, 1994), which has been documented to occur in nodules of regenerative liver tissue.”
Background
Research works printed but not linked: 5
- Dionisi‐Vici C, 1997, Tyrosinemia type I with early metastatic hepatocellular carcinoma: combined treatment with NTBC, chemotherapy and surgical mass removal, J Inher Metab Dis, 20, 15
- Holme E, 1995, Treatment of tyrosinemia type I with an enzyme inhibitor, Int Pediatr, 10, 41
- Kerckaert I, 1997, Secondary alterations of hepatic peroxisomes in tyrosinaemia type I: morphometry and electron microscopy, J Inher Metab Dis, 20, 13
- Segel I, 1975, Enzyme Kinetics
- Vilaseca MA, 1997, Chronic form of tyrosinaemia type I: late‐onset treatment with NTBC, J Inher Metab Dis, 20, 10
Cited by
Sorted by citations
Murray, K. F., & Carithers, R. L. (2005) · Hepatology · doi:10.1002/hep.20704 · Cited by 933
Knisely, A. S., Strautnieks, S. S., Meier, Y., Stieger, B., Byrne, J. A., Portmann, B. C., Bull, L. N., Pawlikowska, L., Bilezikçi, B., Özçay, F., et al. (2006) · Hepatology · doi:10.1002/hep.21287 · Cited by 377
4-Hydroxyphenylpyruvate dioxygenase
Moran, G. R. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.08.015 · Cited by 306
Chinsky, J. M., Singh, R., Ficicioglu, C., van Karnebeek, C. D. M., Grompe, M., Mitchell, G., Waisbren, S. E., Gucsavas-Calikoglu, M., Wasserstein, M. P., Coakley, K., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.101 · Cited by 247
Recommendations for the management of tyrosinaemia type 1
de Laet, C., Dionisi-Vici, C., Leonard, J. V., McKiernan, P., Mitchell, G., Monti, L., de Baulny, H. O., Pintos-Morell, G., & Spiekerkötter, U. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-8 · Cited by 227
Metadata
- Authors
- Holme, E., & Lindstedt, S.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 1998-08
- Volume
- 21
- Issue
- 5
- Pages
- 507-517
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W1567009066
- Cited by
- 264
- References
- 17
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 4 · 2023: 6 · 2022: 9 · 2021: 7 · 2020: 6 · 2019: 10 · 2018: 2 · 2017: 18 · 2016: 7 · 2015: 8 · 2014: 14 · 2013: 11 · 2012: 7
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Inherited Metabolic Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Swedish Cancer Foundation
- Vetenskapsrådet
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
- Keywords
- NTBC, tyrosine catabolism, hepatocellular carcinoma prevention, liver transplantation, succinylacetone, early treatment initiation, treatment response
- MeSH terms
- Amino Acid Metabolism, Inborn Errors, Animals, Clinical Trials as Topic, Cyclohexanones, Enzyme Inhibitors, Humans, Nitrobenzoates, Tyrosine, 4-Hydroxyphenylpyruvate Dioxygenase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione). https://app.cochat.ai/papers/10.1023/a:1005410820201
- The paper
- Holme, E., & Lindstedt, S. (1998). Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione). Journal of Inherited Metabolic Disease. https://doi.org/10.1023/a%3A1005410820201
